Učitavanje...
Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
OBJECTIVES: Guidelines cautioned prescribing of tumour necrosis factor inhibitors (TNFi) to patients with rheumatoid arthritis and interstitial lung disease (RA-ILD) after reports of new or worsening of ILD. Less is known about outcomes among patients with RA-ILD who receive rituximab (RTX). This st...
Spremljeno u:
| Izdano u: | RMD Open |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMJ Publishing Group
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5604605/ https://ncbi.nlm.nih.gov/pubmed/28955489 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2017-000473 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|